Promaxo Holdings, Inc., a medical imaging, robotics, and AI technology company based in Oakland, California, announced five system sales in January 2023, bringing total sales to 30 MRI systems and approximately $18.3 million since commercial launch in Q4 2021.
The systems were sold to:
- Mount Sinai Health System (NY)
- UTHealth Houston, The University of Texas Health Science Center at Houston (TX)
- Urology Care of Central New Jersey (NJ)
- Yalkut Urology (KY)
- University Hospital Tuebingen (Germany)
Founder and CEO Dr. Amit Vohra stated: “We are off to a solid start in 2023, with five system sales in the month of January alone putting us ahead of plan for the first quarter.”
Promaxo’s single-sided MRI with AI-based imaging is FDA-cleared for in-office use and guides prostate interventions. The company operates with over 200 patents and focuses on minimally-invasive, patient-centric medical imaging solutions.